{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:48:21Z","timestamp":1790995701097,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007831","name":"Capital Health Development","doi-asserted-by":"crossref","award":["201614035"],"award-info":[{"award-number":["201614035"]}],"id":[{"id":"10.13039\/100007831","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CAMS Major Collaborative Innovation Project","award":["2016-I2M-1-011"],"award-info":[{"award-number":["2016-I2M-1-011"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To investigate the effect of two clinically applied proprotein convertase subtilisin\/kexin type 9 monoclonal antibodies (PCSK9\u2010mAbs) on glycaemia and new\u2010onset diabetes mellitus (NODM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, MEDLINE, Embase, Cochrane databases and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      websites were systematically searched for randomized controlled trials that reported data on fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) or NODM incidence. Risk ratios (RRs) for NODM and mean difference (MD) for FPG and HbA1c with 95% confidence intervals (CIs) were calculated using a fixed\u2010effect model. Heterogeneity was examined using the\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      statistic and potential publication bias was assessed using funnel plots and Egger\u2019s test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 18 studies including 26\u2009123 participants without diabetes were identified. No significant difference was observed in the PCSK9\u2010mAb treatment groups in terms of NODM (RR 1.05, 95% CI 0.95\u20101.16), FPG (MD 0.00\u2009mmol\/L, 95% CI \u22120.02 to 0.02) or HbA1c (MD 0.00% [0 mmol\/L], 95% CI \u22120.01 to 0.01) compared with control groups. Subgroup (PCSK9\u2010mAb type, participant characteristics, treatment duration, treatment method and differences in control treatment) and sensitivity analyses did not significantly alter the results. Meta\u2010regression analyses showed that risk of NODM was not associated with baseline age, baseline body mass index (BMI), proportion of men, treatment duration or percent LDL cholesterol reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Alirocumab and evolocumab, two types of PCSK9\u2010mAb approved by the US Food and Drug Administration and the European Medicines Agency, had no significant impact on NODM and glucose homeostasis, regardless of PCSK9\u2010mAb type, participant characteristics, treatment duration, treatment method and differences in control treatment. Baseline age, BMI, proportion of men, treatment duration, and percent change of LDL cholesterol did not influence diabetes risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.13235","type":"journal-article","created":{"date-parts":[[2018,1,29]],"date-time":"2018-01-29T14:22:13Z","timestamp":1517235733000},"page":"1391-1398","source":"Crossref","is-referenced-by-count":57,"title":["Effect of proprotein convertase subtilisin\/kexin type 9 (\n                    <scp>PCSK9<\/scp>\n                    ) monoclonal antibodies on new\u2010onset diabetes mellitus and glucose metabolism:\n                    <scp>A<\/scp>\n                    systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"20","author":[{"given":"Ye\u2010Xuan","family":"Cao","sequence":"first","affiliation":[{"name":"Division of Dyslipidaemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Centre for Cardiovascular Diseases Chinese Academy of Medical Sciences, Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui\u2010Hui","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Dyslipidaemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Centre for Cardiovascular Diseases Chinese Academy of Medical Sciences, Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu\u2010Ting","family":"Dong","sequence":"additional","affiliation":[{"name":"Division of Dyslipidaemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Centre for Cardiovascular Diseases Chinese Academy of Medical Sciences, Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Dyslipidaemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Centre for Cardiovascular Diseases Chinese Academy of Medical Sciences, Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-4364","authenticated-orcid":false,"given":"Jian\u2010Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Dyslipidaemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Centre for Cardiovascular Diseases Chinese Academy of Medical Sciences, Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030442","article-title":"Projections of global mortality and burden of disease from 2002 to 2030","volume":"3","author":"Mathers CD","year":"2006","journal-title":"PLoS Med"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-012-0313-7"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.036"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.14568"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1710"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61183-1"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2215"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.27615"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2015.1042908"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.007"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2009.12.018"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.10.138"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(16)30396-5"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw292"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.07.047"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1464"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16951"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61771-1"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201832"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.144055"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60771-5"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316222"},{"key":"e_1_2_5_27_1","first-page":"2996","article-title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","volume":"36","author":"Kastelein JJ","year":"2015","journal-title":"Eur Heart J"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.06.049"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1520"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.11.010"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501031"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.08.043"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-016-6685-y"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.10.021"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.025080"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500858"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.07.008"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0358-8"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701488"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.1206"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.08.005"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13235","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:16:44Z","timestamp":1761873404000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/dom.13235"],"URL":"https:\/\/doi.org\/10.1111\/dom.13235","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]}}}